Cipher Pharmaceuticals Reports Q4 & FY2017 Results

Wednesday, February 28, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

(IN THOUSANDS OF U.S. DOLLARS) 

2017

2016

$

$

Income from continuing operations

10,747

4,219

Add back:

Depreciation and amortization

967

1,121

Interest expense, net

5,292

7,723

Income taxes

3,518

1,492

EBITDA

20,524

14,555

Change in fair value of derivative financial instrument

(34)

(1,175)

Loss (gain) from the translation of Canadian cash balances

35

(10)

Loss on debt extinguishment

5,223

-

Impairment of intangible assets

561

-

Share-based compensation

338

1,405

Adjusted EBITDA

26,647

14,775



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store